ArticleMedical oncology (Northwood, London, England)2024

A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure.

Mitsuru Okuno et al.PubMed ↗Publisher ↗

No numbers read from the abstract.